about
Prevention of lymphocele development in gynecologic cancers by the electrothermal bipolar vessel sealing deviceCXCL14-CXCR4 and CXCL12-CXCR4 Axes May Play Important Roles in the Unique Invasion Process of Endometrioid Carcinoma With MELF-Pattern Myoinvasion.Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancerIdentification of appropriate cone length to avoid positive cone margin in high grade cervical intraepithelial neoplasia.Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma.Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan.Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.Cytological nuclear atypia classification can predict prognosis in patients with endometrial cancer.Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer.Clinicopathologic features of brain metastases from gynecologic malignancies: a retrospective study of 139 cases (KCOG-G1001s trial).Treatment and prognosis of bone metastasis from cervical cancer (KCOG-G1202s).Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary.Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma.Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis.Clinicopathological significance of cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia.Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancerApplicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup studyPilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancerPolypoid endocervical adenomyoma: a case report with clinicopathologic analysesFeasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical HysterectomyNuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancerPostoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067)Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131)A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysisAnalysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional studyChanges in the Clinicopathological Demographics of Vulvar Cancer in Japan: Increasing Oldest-Old, Stage Shifting, and Decreasing Cohort-Level Survival †
P50
Q33917346-09E68E85-CA09-493C-826C-AE8CF855BE4CQ36301979-57F486E3-8E0F-4F97-8987-DAC8C9657EEBQ36641182-6FC4E7D6-4A8D-41C1-91B4-F5A5A7E3BFACQ37092801-2D61C6CB-79F6-4766-B41D-341DFF6DA228Q37345331-ADBBC43A-2AB9-4FAC-B72A-AD8E41E8ED6CQ38088427-4BD8960C-A83B-4815-ACFA-031D6433332EQ38828572-83C00C02-19A9-4444-BF2E-69B68DDDCB32Q38925406-B4BD8DCD-F54A-4F2C-B35D-75118E66C0C5Q40818758-51A4DF7F-2013-4E78-AC9D-C3446B976D51Q44155114-902A0012-1370-49A5-BA88-707D02510830Q44325113-461DC3F0-BC71-43DD-8797-6155A84D7A64Q46753331-B7F2D131-86B3-4F93-B19F-DB19DBD9C1A5Q48300984-66ADF442-4691-43D5-AA76-4F4C47990274Q53158857-82692F5C-4AD1-4E01-B3AF-C33B14781C22Q53251980-A8E6ECE9-10A6-49E4-9CCA-BD8E3D6244FEQ53497657-9846FF46-F176-4D69-B66D-A26EC9F1098AQ54249091-F26BBB38-994D-47B4-A1E0-7D6E7833E3DEQ54771083-E46D8074-8B7A-4795-B473-A5A2514D65C7Q58767926-A0183687-4D45-4B2A-8C34-9D75B733A1EFQ63199198-BA3ABFEB-EBEB-435C-B2D6-9278E53251FBQ80326717-F720F06F-69A4-4907-8C6A-C102940478A3Q80498708-4F2C09CE-0C81-4EA8-A24C-2703B577EB99Q87186079-15F7354F-813E-42B5-9D30-0C7B914AA84BQ87213621-02BDC717-494E-4822-9A66-99BF2EE5CE07Q88375444-10610561-1BC2-4735-9989-07433457E379Q89507041-B64F71A6-F066-486D-A80B-BECFBED75092Q90326455-C683D821-55E9-4D15-9CB8-81CEAC73C419Q90422897-A48F1C94-E8AE-4A9E-A9D7-D2D5CB6FC6E2Q91311048-12108B88-0952-4F05-8864-77E9CA4566B8Q91645936-69878905-217B-4EDB-871B-1AD34776B38D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Shin Nishio
@ast
Shin Nishio
@en
Shin Nishio
@es
Shin Nishio
@nl
Shin Nishio
@sl
type
label
Shin Nishio
@ast
Shin Nishio
@en
Shin Nishio
@es
Shin Nishio
@nl
Shin Nishio
@sl
prefLabel
Shin Nishio
@ast
Shin Nishio
@en
Shin Nishio
@es
Shin Nishio
@nl
Shin Nishio
@sl
P106
P31
P496
0000-0003-2526-630X